Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ohio
Clinical trial register · United States · industry-sponsored

Clinical Trials in Ohio, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca36 Novartis Pharmaceuticals28 Hoffmann-La Roche25 Merck Sharp & Dohme LLC20 GlaxoSmithKline19
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Ohio

1263 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
NCT07703436Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma
DrugSafusidenib
Nuvation Bio Inc.
Phase 2
40
California, Connecticut, Florida, Indiana, New Jersey, New York, Ohio
2027-03
Not yet open
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07848295Clear Cell Renal Cell Carcinoma (ccRCC)
DrugsCabozantinib·Opdivo·Nivolumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
112
Connecticut, New Jersey, New York, Ohio, Texas, Washington
2026-12-31
Recruiting
SPI-1005 in Adults Receiving Cochlear Implant
NCT06340633Hearing Loss, Cochlear Trauma
DrugEbselen
Sound Pharmaceuticals, Incorporated
Phase 2
40
Iowa, Ohio, Pennsylvania, South Carolina, Texas, Wisconsin
2026-12
Not yet open
Prescriptive Infusion Algorithm (PIA)
NCT07215403PARKINSON DISEASE (Disorder)
DrugAB-1005
AskBio Inc
Phase 2
18
Ohio, Pennsylvania, South Carolina
2026-11
Not yet open
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
NCT07793942Malignant Neoplam, Advanced Solid Tumors
DrugsMK-2010·Belzutifan·Fluorouracil·Leucovorin
Merck Sharp & Dohme LLC
Phase 2
480
New Jersey, Ohio, Oregon
2026-10-27
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
DrugMezagitamab
Takeda
Phase 2
36
California, Florida, Maryland, Missouri, New Jersey, New York, Ohio, Texas
2026-10-15
Not yet open
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649Endometrial Neoplasms, Endometrial Cancer
DrugsPF-08634404·Keytruda·Pembrolizumab
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, Ohio, Oregon, Tennessee, Texas, Virginia
2026-10-09
Recruiting
a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers
NCT07852338Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Applied Biologics, LLC
Phase 3
253
Ohio
2026-10-08
Recruiting
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07811869Chronic Pruritus of Unknown Origin
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Florida, Massachusetts, Michigan, Ohio
2026-10-06
Not yet open
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
NCT07845500Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
DrugsBerobenatide·Tirzepatide·Semaglutide
Pfizer
Phase 3
660
Alabama, Florida, Kentucky, Michigan, Missouri, Montana, North Carolina, Ohio
2026-10-01
Not yet open
Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline With the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS)
NCT07793981Post Surgical Respiratory Failure, Respiratory Complication, Opioid Induced Respiratory Depression, Respiratory Arrest
Linshom Medical, Inc.
Not applicable
394
Maryland, Ohio
2026-10-01
Recruiting
Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area
NCT07035431Anastomotic Leaks, Hartmanns Stump Leakage
Boston Scientific Corporation
Not applicable
66
California, Florida, Massachusetts, New York, Ohio, Pennsylvania, Washington, West Virginia
2026-10
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
DrugZenpep
Aimmune Nestlé Health Science US R&D, LLC
Phase 2
66
Arizona, Arkansas, California, Florida, Kansas, Maryland, Montana, Ohio
2026-10
Not yet open
Signatera Assessment in Early-Stage Endometrial Cancer
NCT07339384Endometrial Cancer
Natera, Inc.
Not applicable
1,010
Alabama, California, Florida, Illinois, Minnesota, New York, North Carolina, Ohio
2026-10
Not yet open
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
NCT07526974Subcutaneous Fat
DrugCBL-514
Caliway Biopharmaceuticals Co., Ltd.
Phase 3
320
California, Florida, Georgia, Maryland, Nebraska, New York, Ohio, Tennessee
2026-10
Recruiting
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
NCT07840326Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
Sundance Biosciences, Inc.
Phase 2
20
Georgia, North Carolina, Ohio
2026-10
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
California, Florida, Illinois, Maryland, Massachusetts, New York, Ohio, Tennessee
2026-09-30
Recruiting
A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections
NCT07379684Surgical Wound Infection, Traumatic Wound Infection
Macro Biologics, Inc.
Phase 1
44
California, Idaho, Maryland, Missouri, Ohio
2026-09-30
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Alaska, Maryland, Michigan, New York, Ohio, Pennsylvania, West Virginia
2026-09-29
Recruiting
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945Geographic Atrophy
Biojiva LLC
Phase 1/2
152
Arizona, Mississippi, Nevada, Ohio, Texas, Utah, Washington
2026-09-29
Not yet open
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
NCT07839871Respiratory Syncytial Virus (RSV)
DrugRSVpreF
Pfizer
Phase 3
920
Ohio
2026-09-28
Recruiting
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
NCT07828860Hidradenitis Suppurativa (HS)
DrugSoquelitinib
Corvus Pharmaceuticals, Inc.
Phase 1
25
Indiana, Kentucky, Massachusetts, New York, North Dakota, Ohio, Pennsylvania, Tennessee
2026-09-17
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289Ocular Myasthenia Gravis
DrugRozanolixizumab
UCB Biopharma SRL
Phase 3
100
Ohio
2026-09-16
Recruiting
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
NCT07851025Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
950
Florida, Maryland, Montana, Ohio
2026-09-16
Not yet open
Healthy Person Eats, Takes 1 Dose, Tested for Drowsiness, Fall Risk, Then Takes Second Dose Followed by Same Tests
NCT07801066Healthy Participants
DrugMetaxalone
Primus Pharmaceuticals
Phase 4
20
Ohio
2026-09-15
Recruiting
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
NCT07743580SARS-CoV-2
DrugSecutrelvir
Shionogi
Phase 3
2,000
Florida, Ohio
2026-09-14
Recruiting
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
NCT07743151Healthy
Merck Sharp & Dohme LLC
Phase 1
400
Florida, New Jersey, Ohio
2026-09-10
Recruiting
Evaluation of Approved Contact Lenses (CR-6657)
NCT07819305Visual Acuity
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Illinois, New York, Ohio, Tennessee, Texas, Virginia
2026-09-10
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig
Bristol-Myers Squibb
Phase 2
160
District of Columbia, Georgia, Kentucky, Maryland, Mississippi, Nebraska, New York, Ohio
2026-09-10
Recruiting
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
NCT07602855Neoplasms, Lung
DrugsRisvutatug rezetecan·Ivonescimab
GlaxoSmithKline
Phase 1/2
184
California, North Carolina, Ohio
2026-09-09
Not yet open
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults
NCT07819097Adult, Healthy Participants
DrugRSVpreF
Pfizer
Phase 3
600
Connecticut, Ohio, Pennsylvania, Utah, Virginia
2026-09-09
Recruiting
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
NCT07814248NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
TwoStep Therapeutics, Inc.
Phase 1
74
Ohio, Oregon, Virginia
2026-09-02
Recruiting
MBA Early Feasibility Study
NCT07564375Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs), Thoracic Aortic Dissection, Pseudoaneurysm
W.L.Gore & Associates
Not applicable
20
California, Ohio, Texas
2026-09-02
Recruiting
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
NCT07759154Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
80
Florida, Louisiana, Massachusetts, Missouri, Nevada, New Jersey, New York, Ohio
2026-09-01
Recruiting
EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States)
NCT07517588Mitral Regurgitation
Polares Medical SA
Not applicable
15
Georgia, New York, Ohio
2026-09-01
Not yet open
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
NCT07808697SARS-CoV-2
DrugsMRNA-1283·Efluelda (TIV-HD) and Spikevax
ModernaTX, Inc.
Phase 2
300
California, Florida, Illinois, Michigan, Ohio, Texas, Utah, Virginia
2026-09-01
Not yet open
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
NCT07679919Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma
DrugLMY-922
Luminary Therapeutics
Phase 1
27
Ohio
2026-09
Not yet open
Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens Wearers
NCT07829419Astigmatism, Myopia
CooperVision International Limited (CVIL)
Not applicable
60
New York, Ohio, Texas
2026-09
By invitation
VitaSmart HOPE System: Bridge to HOPE Registry
NCT07578441End Stage Liver DIsease, Liver Failure
Bridge to Life Ltd.
Observational
5,000
Ohio
2026-09
Recruiting
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
NCT07804186Uveal Melanoma
DrugsDarovasertib·Crizotinib
IDEAYA Biosciences
Phase 3
450
Arizona, California, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania
2026-09
Recruiting
MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
NCT07332182Osteochondral Lesions of the Knee Joint, Osteochondritis Dissecans (OCD), Early Osteoarthritis
Fin-Ceramica Faenza Spa
Not applicable
400
Ohio
2026-09
Recruiting
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870Locally Advanced Basal Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Florida, Georgia, New York, Ohio, Texas
2026-09
Not yet open
Reduction of Anxiety Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07140497Hearing Disability, Anxiety, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
California, Georgia, Massachusetts, North Carolina, Ohio, Texas
2026-09
Not yet open
Reduction of Depression Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07195292Hearing Disability, Depression, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Recruiting
A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)
NCT07820085Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP), EPP2
Portal Therapeutics, Inc.
Phase 2/3
225
California, Ohio
2026-09
Recruiting
A Study of COVID-19 Vaccine(s) in Children and Adults
NCT07798648COVID-19 Vaccines
DrugComirnaty
BioNTech SE
Phase 3
700
Florida, Georgia, Hawaii, Kentucky, Ohio, Pennsylvania, Texas, Utah
2026-08-31
Not yet open
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)
DrugsASCT·AZD0120·Melphalan·Lenalidomide
AstraZeneca
Phase 3
750
Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington
2026-08-25
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
NCT07772492Severe Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
300
California, Florida, Idaho, Indiana, Nebraska, Ohio, Texas
2026-08-24
Recruiting
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07700056Chronic Pruritus of Unknown Origin
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Florida, Georgia, Indiana, New York, Ohio, South Carolina, Texas
2026-08-24
Recruiting
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
NCT07214376Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
Pulnovo Medical, Inc.
Not applicable
750
Arizona, Louisiana, Massachusetts, Michigan, New York, Ohio, Oklahoma, Pennsylvania
2026-08-21
Recruiting
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263Schizophrenia
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
472
Arkansas, California, Florida, Georgia, Illinois, Maryland, Ohio, Oklahoma
2026-08-20
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
NCT07585968Ventricular Tachycardia
Medtronic Cardiac Ablation Solutions
Not applicable
260
Indiana, New York, North Carolina, Ohio, Texas
2026-08-17
Recruiting
Pacritinib Effectiveness in Real-world Settings
NCT07774455Myelofibrosis (MF)
Swedish Orphan Biovitrum
Observational
60
Connecticut, Ohio, South Carolina
2026-08-13
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT07540897Narcolepsy Type 1
DrugAlixorexton
Alkermes, Inc.
Phase 3
150
Florida, Georgia, Michigan, Missouri, North Carolina, Ohio, South Carolina, Texas
2026-08-13
Recruiting
A Study of V132 in Healthy Older Participants (V132-001)
NCT07712575Healthy
DrugsCapvaxive·Prevnar 20
Merck Sharp & Dohme LLC
Phase 1
280
California, Florida, Missouri, Nebraska, Ohio, Rhode Island, Texas
2026-08-12
Recruiting
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
NCT07734064Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Institute for Regenerative Medicine
Phase 1
30
Arizona, Ohio, Texas
2026-08-10
Not yet open
Comparing Facial Aging Between Identical Twins With 3D Imaging
NCT07760532Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
DrugsTirzepatide·Semaglutide
Ponsky Facial Aesthetics And Plastic Surgery, Llc
Observational
200
Ohio
2026-08-08
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
New Jersey, Ohio, Oklahoma, Tennessee
2026-08-06
Recruiting
Within-Subject Comparison of Adipose Tissue Viability Following Liposuction
NCT07820397Liposuction
Apyx Medical
Not applicable
30
Ohio, Washington
2026-08-06
Recruiting
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
NCT07612267Lactation, Inflammatory Bowel Disease
DrugMirikizumab
Eli Lilly and Company
Phase 4
14
Illinois, Iowa, Maryland, New York, Ohio
2026-08-05
Recruiting
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
NCT07494045CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
OPKO Health, Inc.
Phase 2
40
Missouri, Ohio, Pennsylvania, South Carolina, Wisconsin
2026-08-05
Recruiting
Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation
NCT07335523Exocrine Pancreatic Insuficiency
Digestive Care, Inc.
Observational
30
Colorado, New York, Ohio, Oregon, Tennessee, Texas, Washington
2026-08-03
Recruiting
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
NCT07723248Metastatic Castration Resistant Prostate Cancer
DrugsRinzimetostat·Xtandi·Taxotere·Darolutamide
ORIC Pharmaceuticals
Phase 3
600
Florida, Indiana, Michigan, North Carolina, Ohio, South Carolina, Tennessee, Texas
2026-08-03
Recruiting
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
NCT07680439Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor
BrainChild Bio, Inc
Phase 2
75
California, Georgia, Illinois, Ohio, Pennsylvania, Washington
2026-08
Not yet open
PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers
NCT07779239Diabetic Foot Ulcers (DFUs)
Oneness Biotech Co., Ltd.
Not applicable
100
Florida, Louisiana, New York, Ohio, Oklahoma, Pennsylvania
2026-08
Not yet open
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
NCT07712562Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse
DrugDibotatug
Dren Bio
Phase 1/2
60
California, Florida, Georgia, New York, Ohio, Texas, Virginia, Washington
2026-08
Recruiting
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
NCT07824583Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers
Varian, a Siemens Healthineers Company
Not applicable
20
Missouri, Ohio
2026-07-31
Not yet open
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
NCT07707674Metastatic Pancreatic Cancer
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1
24
Michigan, New York, Ohio, Oklahoma, Tennessee, Texas
2026-07-30
Recruiting
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
NCT07795164Metabolic Dysfunction-Associated Steatohepatitis (MASH)
DrugPemvidutide
Altimmune, Inc.
Phase 3
1,800
Arkansas, California, Florida, Ohio
2026-07-30
By invitation
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
NCT07620574Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
DrugsZanzalintinib·Abiraterone·Cabozantinib·Enzalutamide
Exelixis
Phase 3
5,000
New York, Ohio
2026-07-30
Recruiting
Hybrid Delivery to Increase Access and Sustainability: Evaluating ezParent Implementation
NCT07417930Parenting, Prevention, Program Implementation, Early Childhood
Klein Buendel, Inc.
Not applicable
516
Ohio
2026-07-27
Recruiting
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
NCT07725939Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
DrugGalvokimig
UCB Biopharma SRL
Phase 2
402
Ohio, Pennsylvania, Texas
2026-07-27
Recruiting
Autus Valve Continued Access Study (CAS)
NCT07466745Congenital Heart Disease
Edwards Lifesciences
Not applicable
36
California, Colorado, Georgia, Massachusetts, Michigan, New York, North Carolina, Ohio
2026-07-27
Recruiting
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
NCT07681596Relapsed or Refractory Multiple Myeloma
DrugsAldesleukin·Daratumumab
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
NCT07585266Gastrointestinal Stromal Neoplasms
DrugsVelzatinib·Imatinib
GlaxoSmithKline
Phase 3
800
Arizona, California, Connecticut, Maryland, Nebraska, New York, Ohio, Tennessee
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
A Study to Evaluate MAR002 for Acromegaly
NCT07641179Acromegaly
DrugMAR002
Marea Therapeutics
Phase 2
72
Arizona, Ohio, Texas
2026-07-23
Recruiting
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07704892Metabolic Dysfunction-associated Steatohepatitis
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
380
Arkansas, California, Florida, Missouri, New York, North Carolina, Ohio, Texas
2026-07-22
Recruiting
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
NCT07635563Obstructive Sleep Apnea (OSA)
DrugAcetazolamide
Incannex Healthcare Ltd
Phase 2
120
California, Florida, Louisiana, Maryland, Ohio, South Carolina, Tennessee, Texas
2026-07-21
Recruiting
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
NCT07366034Fibrosing Interstitial Lung Disease
DrugNerandomilast
Boehringer Ingelheim
Phase 3
35
California, Colorado, Maryland, Massachusetts, Minnesota, Ohio, Pennsylvania
2026-07-21
Recruiting
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
NCT07390344Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
W.L.Gore & Associates
Observational
152
Georgia, Minnesota, Ohio
2026-07-20
By invitation
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
NCT07102511Familial Hypercholesterolemia - Heterozygous
DrugLerodalcibep
LIB Therapeutics LLC
Phase 3
150
Ohio
2026-07-20
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsRilvegostomig·Enfortumab Vedotin·Dato-DXd·Opdivo
AstraZeneca
Phase 3
915
Arkansas, California, Illinois, Massachusetts, Missouri, Nebraska, New York, Ohio
2026-07-16
Recruiting
Mako-MORE Registry
NCT07647354Arthropathy of Knee, Arthropathy of Hip
Stryker Orthopaedics
Observational
950
Florida, Kentucky, New York, Ohio, Rhode Island
2026-07-13
Recruiting
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
NCT07625280Narcolepsy, Idiopathic Hypersomnia
DrugXywav
Jazz Pharmaceuticals
Phase 3
120
California, Ohio
2026-07-09
Recruiting
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
NCT07575269Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
571
Arkansas, Georgia, Iowa, New York, Ohio, Pennsylvania, South Carolina, Texas
2026-07-07
Recruiting
Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System
NCT07503236Mitral Regurgitation Functional
Nyra Medical, Inc.
Not applicable
30
California, Michigan, Ohio
2026-07-02
Recruiting
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Kardigan, Inc.
Phase 2
140
Colorado, Florida, Illinois, Michigan, New York, Ohio, South Carolina, Tennessee
2026-06-23
Recruiting
Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis
NCT07122518Pulmonary Artery Stenosis
Cordis US Corp.
Observational
35
California, Georgia, Michigan, Missouri, Nebraska, Ohio, Pennsylvania, Texas
2026-06-23
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide
Hoffmann-La Roche
Phase 3
380
California, Connecticut, District of Columbia, Georgia, North Carolina, Ohio, West Virginia
2026-06-23
By invitation
An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD
NCT07670702Post Traumatic Stress Disorder
DrugMethylone
Transcend Therapeutics
Phase 3
300
Arkansas, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Ohio
2026-06-22
Recruiting
ColoSeal™ ICD System Anastomotic Protection Pivotal Study
NCT07429110Rectal Cancer Surgery
Averto Medical, Inc.
Not applicable
250
Florida, Ohio, South Carolina, Tennessee, Utah
2026-06-19
Recruiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
NCT07588100Diabetic Retinopathy
Hoffmann-La Roche
Phase 1
30
California, Illinois, Ohio
2026-06-18
Recruiting
A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)
NCT07606274LMNA-Related Dilated Cardiomyopathy
Nuevocor Pte. Ltd.
Phase 1/2
21
Alabama, California, Massachusetts, Michigan, Minnesota, Ohio, Texas
2026-06-16
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NCT07632001Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Reprise Biomedical, Inc.
Not applicable
180
Arizona, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma, Texas
2026-06-15
Recruiting
Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease
NCT07514338Mitochondrial Diseases
DrugNapazimone
Pharming Technologies B.V.
Phase 2
140
Ohio
2026-06-12
Not yet open
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
NCT07607925Lymphoma, Non-Hodgkin
DrugGSK5926371
GlaxoSmithKline
Phase 1/2
49
Ohio
2026-06-12
Recruiting
Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease
NCT07017634Degenerative Disc Disease
CGBio Inc.
Phase 3
316
Arkansas, California, Florida, Louisiana, Ohio, Pennsylvania, Texas, West Virginia
2026-06-11
Recruiting
Testing of GripTract-GI Endoscopic Tissue Manipulator for Use During Complex Endoscopic Polypectomies in the Colon
NCT06015607Polyps Colorectal
Actuated Medical, Inc.
Not applicable
30
Ohio
2026-06-11
Recruiting
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
NCT06622057Biliary Tract Cancer (BTC)
DrugD07001-Softgel
InnoPharmax Inc.
Phase 3
240
Arizona, Florida, Ohio
2026-06-09
Recruiting
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07593391Phelan-McDermid Syndrome
DrugNNZ-2591
Neuren Pharmaceuticals Limited
Phase 3
180
Alabama, California, Maryland, Massachusetts, New York, Ohio, Texas
2026-06-08
By invitation
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
NCT07734415Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
DrugIMG-007
Inmagene LLC
Phase 2
400
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2026-06-05
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
NCT07633301Narcolepsy Type 1
DrugTAK-360
Takeda
Phase 2
92
California, Florida, Ohio
2026-06-04
Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334Stargardt Disease
DrugALK-001
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
NCT07586618Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc
Phase 1
24
Colorado, Indiana, New York, Ohio, Pennsylvania, Texas
2026-06-01
Recruiting
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
NCT07227350Locally Advanced Basal Cell Carcinoma
DrugsDaromun·L19IL2·Onfekafusp alfa
Philogen S.p.A.
Phase 2
180
Florida, Georgia, North Carolina, Ohio, Texas
2026-06-01
Not yet open
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
NCT07676097Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
AngioInsight
Observational
620
California, District of Columbia, Minnesota, New Jersey, New York, Ohio, Tennessee
2026-06
Recruiting
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
NCT07598708Narcolepsy Type 1, Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Mississippi, North Carolina, Ohio, South Carolina
2026-05-29
Recruiting
NORM-HF Pivotal Study
NCT07574593Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
Foundry Innovation & Research 1, Limited (FIRE1)
Not applicable
800
California, Florida, New York, Ohio, Oklahoma, Pennsylvania, South Dakota
2026-05-29
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Indiana, Maryland, New Jersey, New York, Ohio
2026-05-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521Ocular Myasthenia Gravis
DrugRozanolixizumab
UCB Biopharma SRL
Phase 3
120
Arizona, Illinois, New York, Ohio, Wisconsin
2026-05-27
Recruiting
Clareon TruPlus Study
NCT07502456Aphakia, Astigmatism
Alcon Research
Not applicable
122
Arizona, Ohio, South Carolina, Texas, Utah
2026-05-26
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266Polycythemia Vera
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Florida, Georgia, Maryland, Michigan, New York, Ohio
2026-05-25
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282High Risk Smoldering Multiple Myeloma (HR-SMM)
DrugsLinvoseltamab·Darzalex·Daratumumab
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2026-05-21
Recruiting
Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population
NCT07623902CRC Screening, Microbiome
Jubaan Ltd.
Not applicable
1,436
Alabama, California, Florida, Illinois, New York, Ohio, Virginia
2026-05-18
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
Molecular Partners AG
Phase 1/2
138
Florida, Georgia, Maryland, Nebraska, New Jersey, Ohio
2026-05-18
Recruiting
Technology Assisted Treatment for Trichotillomania
NCT05118633Trichotillomania
HabitAware Inc.
Not applicable
90
Ohio
2026-05-15
Recruiting
AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE
NCT07277946Hernia
Tissium
Not applicable
240
California, Florida, Illinois, Kentucky, Michigan, Nebraska, North Carolina, Ohio
2026-05-14
Recruiting
IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery
NCT07346066Ureter Injury
Intuitive Surgical
Phase 3
146
California, Connecticut, Florida, Nevada, Ohio, Texas, Washington
2026-05-14
Recruiting
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
NCT07553429Diabetic Macular Edema
Boehringer Ingelheim
Phase 1/2
49
Arizona, California, Connecticut, Florida, New York, North Carolina, North Dakota, Ohio
2026-05-14
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
A Study of TAK-505 in Adults With Solid Tumors
NCT07436728Malignant Solid Tumors
Takeda
Phase 1/2
151
California, Florida, Minnesota, New York, Ohio, Tennessee, Texas, Virginia
2026-05-11
Recruiting
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
NCT07629557Keratoconus
Glaukos Corporation
Phase 4
15
Ohio
2026-05-11
Recruiting
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
NCT07582432Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
DrugGamunex-C
Grifols Biologicals, LLC
Phase 3
49
Florida, Indiana, Maine, Ohio, Washington
2026-05-11
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156Urothelial Cancer, Urinary Bladder Neoplasms
DrugsMitomycin C·Enfortumab Vedotin·Fluorouracil·Keytruda
Astellas Pharma Global Development, Inc.
Phase 3
390
California, Colorado, Delaware, Illinois, Indiana, Missouri, Ohio, Oregon
2026-05-11
Recruiting
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
NCT07406360Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
GlaxoSmithKline
Phase 3
1,209
Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina
2026-05-11
Recruiting
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
NCT07610837Liver Fibrosis, Hepatic Cirrhosis
AstraZeneca
Phase 2
104
Arizona, Florida, Missouri, Nevada, North Carolina, Ohio, Oklahoma, Tennessee
2026-05-07
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals
Phase 2
99
Colorado, Massachusetts, Nebraska, Ohio
2026-05-06
Recruiting
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT07555483Alpha 1 Antitrypsin Deficiency
Grifols Therapeutics LLC
Phase 3
40
Alabama, Arizona, California, Florida, Minnesota, Ohio, South Carolina, Texas
2026-05-05
Recruiting
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
California, Florida, Georgia, Illinois, New York, Ohio, Pennsylvania, Texas
2026-05-05
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Arizona, Florida, Georgia, Illinois, New York, North Dakota, Ohio, Pennsylvania
2026-05-05
Recruiting
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
NCT07335588Lichen Sclerosus
DrugDelgocitinib
LEO Pharma
Phase 3
652
Alabama, Arizona, California, District of Columbia, Florida, Minnesota, New York, Ohio
2026-05-01
Recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
NCT07502508Type 2 Diabetes
DrugIcovamenib
Biomea Fusion Inc.
Phase 2
60
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-04-30
Recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
DrugsTelisotuzumab Adizutecan·Fluorouracil·Irinotecan·Oxaliplatin
AbbVie
Phase 2/3
900
Connecticut, Illinois, Michigan, Missouri, Ohio, Pennsylvania, Texas, Virginia
2026-04-30
Recruiting
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
NCT07513181Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Athos Therapeutics Inc
Phase 2
120
Florida, Georgia, Ohio
2026-04-30
Recruiting
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
NCT07554521Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine
BeOne Medicines
Phase 2
30
California, Florida, Missouri, Ohio
2026-04-30
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
DrugBrenipatide
Eli Lilly and Company
Phase 2
342
Arizona, California, Florida, Illinois, Indiana, Kentucky, New York, Ohio
2026-04-29
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
New Jersey, New York, Ohio, Washington
2026-04-28
Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512Metastatic Castration-resistant Prostate Cancer (mCRPC)
DrugXaluritamig
Amgen
Phase 1
40
Colorado, North Carolina, Ohio, Pennsylvania, South Dakota, Tennessee, Texas, Virginia
2026-04-28
Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT07232030Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
CVRx, Inc.
Not applicable
2,500
Alabama, Florida, Missouri, Nebraska, Ohio, South Dakota, Tennessee, Texas
2026-04-24
By invitation
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT07271667Chronic Lymphocytic Leukemia, B-cell Malignancies
DrugsEmavusertib·Zanubrutinib
Curis, Inc.
Phase 2
108
Florida, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2026-04-23
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina, Ohio
2026-04-23
Recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT07342478CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed
DrugsRocbrutinib·Pirtobrutinib
Newave Pharmaceutical Inc
Phase 3
306
Illinois, Maryland, Nevada, Ohio, Pennsylvania, Washington
2026-04-23
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
DrugsBNT324·Prednisone/Prednisolone·Docetaxel
BioNTech SE
Phase 3
736
California, Colorado, Florida, Illinois, Maryland, New York, Ohio, Tennessee
2026-04-22
Recruiting
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
NCT07346144Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Trogenix ltd
Phase 1/2
68
Ohio
2026-04-21
Recruiting
Donidalorsen Treatment in Children With Hereditary Angioedema
NCT07298447Hereditary Angioedema (HAE)
DrugDonidalorsen
Ionis Pharmaceuticals, Inc.
Phase 3
20
California, Florida, Louisiana, Missouri, Ohio, Pennsylvania, Wisconsin
2026-04-21
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
DrugBI 3000202
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT07441876Achondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2/3
160
California, Delaware, Illinois, Maryland, Ohio, Pennsylvania, Texas
2026-04-20
Recruiting
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500Ovarian Cancer
DrugAzenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Arizona, California, New Jersey, Ohio, Oregon, Pennsylvania, South Dakota
2026-04-17
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954Diabetes Mellitus, Type 2
DrugsNNC0662-0419·Semaglutide
Novo Nordisk A/S
Phase 2
270
California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio
2026-04-17
Recruiting
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
NCT07439094Advanced Solid Tumors, Non-Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
Phase 1/2
140
Ohio
2026-04-16
By invitation
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
NCT07444489Antibody-mediated Rejection, Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 3
201
California, Minnesota, Missouri, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia
2026-04-16
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugsVisugromab·Visugromab RDE
CatalYm GmbH
Phase 2/3
518
Connecticut, Florida, Georgia, New Jersey, Ohio
2026-04-16
Recruiting
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
NCT06451757Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
DrugSonlicromanol
Khondrion BV
Phase 3
220
Massachusetts, Ohio, Texas
2026-04-14
Recruiting
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
NCT07525375Asthma
AstraZeneca
Phase 2
69
California, Florida, Kentucky, Louisiana, Massachusetts, Missouri, Ohio, Oklahoma
2026-04-14
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Dispatch Biotherapeutics
Phase 1
66
California, Florida, Massachusetts, Ohio, Tennessee, Utah
2026-04-13
Recruiting
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
NCT07298473Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
400
Alabama, California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2026-04-08
Active, closed
A Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults
NCT07287124Hearing Loss, Bilateral Sensorineural
Cochlear
Not applicable
56
Colorado, Florida, Iowa, Michigan, Minnesota, Missouri, New York, Ohio
2026-04-03
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
DrugsRina-S·Bevacizumab
Genmab
Phase 3
544
Florida, Maryland, Ohio
2026-04-03
Recruiting
Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness
NCT07280247Pulmonary Embolism Acute
Angiodynamics, Inc.
Not applicable
39
Minnesota, New York, Ohio, Texas
2026-03-30
Active, closed
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
NCT07502495Type 2 Diabetes
DrugIcovamenib
Biomea Fusion Inc.
Phase 2
64
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-03-27
Recruiting
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
NCT06947941Alzheimer Disease, Psychosis
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
325
Arizona, California, Florida, Ohio
2026-03-25
Recruiting
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577Schizophrenia
DrugLB-102
LB Pharmaceuticals Inc.
Phase 3
456
Arkansas, California, Florida, Georgia, Illinois, Missouri, Ohio
2026-03-25
Active, closed
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
NCT07505303Adult Obesity, Weight Management
DrugsECC4703·Semaglutide
Eccogene
Phase 2
151
Alabama, California, Florida, Georgia, Minnesota, Nebraska, North Carolina, Ohio
2026-03-23
Active, closed
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
NCT07496450Influenza
ModernaTX, Inc.
Phase 3
4,050
California, Georgia, Idaho, Maryland, Nebraska, Ohio, Rhode Island, South Carolina
2026-03-23
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463Multiple Sclerosis (MS) Primary Progressive
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
705
Arizona, California, Florida, Kansas, Missouri, New Jersey, North Carolina, Ohio
2026-03-23
Recruiting
Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)
NCT07510412Venous Leg Ulcers
Organogenesis
Not applicable
200
Ohio
2026-03-18
Recruiting
Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device
NCT07456865Urge Urinary Incontinence
MedtronicNeuro
Not applicable
256
Alabama, Idaho, Missouri, North Carolina, Ohio, Pennsylvania, South Carolina, South Dakota
2026-03-17
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
DrugBevacizumab
Whitehawk Therapeutics, Inc.
Phase 1
265
Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio
2026-03-15
Recruiting
A Trial to Study the Effects of Ginseng and Cordyceps on Aerobic Capacity, Lactate Kinetics, and Nitric Oxide
NCT07729943Healthy Subjects With Low Energy Levels
Applied Food Sciences Inc.
Not applicable
75
Ohio
2026-03-15
Recruiting
Growth and Tolerance of Plant-based Enteral Formulas in Children Ages 12-17 Months.
NCT07231705Formula Dependent Children 1 to 2 Years of Age
Kate Farms Inc
Not applicable
40
Ohio
2026-03-13
Recruiting
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470Kidney Transplant Rejection
DrugsRabbit anti-thymocyte globulin·Frexalimab·Mycophenolate Mofetil·Tacrolimus
Sanofi
Phase 2/3
526
Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York, Ohio
2026-03-13
Recruiting
Bridging the Gap: Enhancing Cancer Care for Underserved Populations With the Veris Health Cancer Care Platform
NCT07396064Cancer Care Recipient, Observational Study
VERIS HEALTH INC
Observational
50
Ohio
2026-03-11
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,182
Arizona, California, Colorado, Florida, Maryland, Ohio, Tennessee, Texas
2026-03-11
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc.
Phase 1/2
160
California, Colorado, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania
2026-03-11
Recruiting
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT07457918Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
600
Florida, Indiana, Ohio, Texas
2026-03-11
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
DrugsIdelalisib·Pirtobrutinib
Eli Lilly and Company
Phase 4
150
Alabama, Arizona, Florida, Minnesota, New York, Ohio, Texas
2026-03-09
Recruiting
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
NCT07226895Clinical High Risk for Psychosis (CHR)
Monument Therapeutics Limited
Phase 1/2
150
California, Connecticut, Massachusetts, Missouri, New York, North Carolina, Ohio, Oregon
2026-03-03
Recruiting
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT07477639Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
DrugBendamustine
Tr1X, Inc.
Phase 1/2
39
California, Kansas, Minnesota, Missouri, New York, North Carolina, Ohio, Washington
2026-03-01
Not yet open
Evaluating Laser Otoscope for Middle Ear Effusion Detection
NCT07454512Middle Ear Effusion, Otitis Media
MSTATT LLC
Observational
150
Ohio
2026-03-01
Not yet open
Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
NCT03176186Post-Cardiac Arrest Syndrome
Invero Pharma, Inc.
Phase 3
1,436
Connecticut, Florida, Mississippi, Nebraska, New York, Ohio, Tennessee, Texas
2026-03
Not yet open
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
NCT07328529Aggressive Behavior in Fragile X Syndome
Azevan Pharmaceuticals
Phase 2
80
California, Illinois, Ohio
2026-03
Recruiting
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
NCT07168993Lung Cancer (Diagnosis)
bioAffinity Technologies Inc.
Not applicable
2,063
California, Colorado, Florida, Illinois, Ohio, Pennsylvania, Texas, Wisconsin
2026-02-25
Recruiting
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
NCT07051707COPD, Chronic Obstructive Pulmonary Disease
Nuvaira, Inc.
Not applicable
200
Alabama, Florida, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, Wisconsin
2026-02-24
Recruiting
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
NCT07148089Catecholaminergic Polymorphic Ventricular Tachycardia
Solid Biosciences Inc.
Phase 1
18
Massachusetts, Minnesota, Ohio, Pennsylvania
2026-02-23
Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Pharma Global Development, Inc.
Observational
90
Arizona, California, Florida, Illinois, Michigan, Mississippi, North Carolina, Ohio
2026-02-20
Recruiting
Study of DISC-0974-201 in Participants With IBD and Anemia
NCT07368972Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia
DrugDISC-0974
Disc Medicine, Inc
Phase 2
21
Alabama, Arizona, California, Florida, Missouri, Ohio, Rhode Island, Texas
2026-02-20
Recruiting
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07335497Locally Advanced / Metastatic Solid Tumors
Crescent Biopharma, Inc.
Phase 1/2
290
Alabama, California, Colorado, District of Columbia, Florida, Michigan, New York, Ohio
2026-02-17
Recruiting
Ambulatory Long Length URodynamics Evaluation
NCT07425015Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics
Bright Uro
Not applicable
101
Louisiana, Maryland, Missouri, Ohio, South Carolina, South Dakota, Texas, Washington
2026-02-17
Recruiting
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
NCT07465835T Cell Malignancies
DrugELA026
Electra Therapeutics Inc.
Phase 1
84
Connecticut, Georgia, Michigan, New York, Ohio, Texas
2026-02-17
By invitation
Validation and Usability Study of the SleepView+ Home Sleep Testing System for the Evaluation of Moderate to Severe Obstructive Sleep Apnea.
NCT07476313Obstructive Sleep Apnea
Beacon Biosignals
Observational
200
California, New York, Ohio, Texas
2026-02-15
Recruiting
Aspiration Thrombectomy Using the Symphony or Prodigy System
NCT07350499Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
Imperative Care, Inc.
Observational
750
Alabama, Florida, Illinois, Indiana, Michigan, New York, Ohio, Virginia
2026-02-13
Recruiting
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury
NCT07455136Traumatic Brain Injury
Hoffmann-La Roche
Observational
2,000
California, Indiana, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee
2026-02-09
Recruiting
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
NCT07232602Bladder Cancer
DrugsMK-3120·Enfortumab Vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
55
California, Illinois, New York, Ohio, Utah
2026-02-09
Recruiting
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
NCT07365462Tardive Dyskinesia
Neurocrine Biosciences
Phase 2
100
Arkansas, California, Florida, Georgia, Nebraska, Ohio, Texas
2026-02-06
Recruiting
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
NCT07226791Ventral Hernia
DrugAGN-151607-DP
AbbVie
Phase 2
200
California, Florida, Illinois, Kansas, Minnesota, North Carolina, Ohio, Pennsylvania
2026-02-04
Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07325136Relapsed/Refractory Small Cell Lung Cancer
DrugPumitamig
Bristol-Myers Squibb
Phase 1/2
240
Michigan, New York, North Carolina, Ohio, Tennessee
2026-02-03
Recruiting
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
NCT07214311Prosthetic-joint Infection
Peptilogics
Phase 2/3
240
Florida, Louisiana, Maryland, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2026-02-03
Recruiting
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH
Phase 2/3
300
California, Indiana, Mississippi, Missouri, New York, Ohio, Oregon, Vermont
2026-02-02
Recruiting
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360Sickle Cell Disease
CSL Behring
Phase 2
63
Arkansas, California, Florida, Georgia, Maryland, Mississippi, New York, Ohio
2026-02-02
Recruiting
A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
NCT06594393Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Xinnate AB
Phase 2
32
Ohio
2026-01-30
Recruiting
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT06875128Metastatic Breast Cancer in the Liver
DrugCapecitabine
Delcath Systems Inc.
Phase 2
90
Florida, Ohio, Texas
2026-01-29
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 3
166
California, Florida, Georgia, Illinois, Massachusetts, New York, Ohio, Tennessee
2026-01-29
Recruiting
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
NCT07024316Congenital Erythropoietic Porphyria (CEP)
Atlas Molecular Pharma
Phase 1/2
6
Ohio
2026-01-29
Active, closed
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
DrugTAK-861
Takeda
Phase 3
98
California, Florida, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Texas
2026-01-29
Recruiting
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
NCT07225621Glioblastoma, GBM
Alpheus Medical, Inc.
Phase 2
103
Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2026-01-28
Recruiting
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.
NCT07665268Skin Ulcer, Pressure Ulcer (PU), Pressure Ulcer of Skin, Pressure Sore
Sequence LifeScience, Inc.
Phase 4
2,000
Ohio
2026-01-28
Recruiting
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
NCT07154823Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Tempus AI
Observational
550
Iowa, Maryland, Missouri, Nevada, North Carolina, Ohio, Pennsylvania, South Dakota
2026-01-27
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
DrugsDifluoromethylornithine·DFMO·Capivasertib·Fulvestrant
Aminex Therapeutics, Inc.
Phase 1/2
92
Arizona, California, Colorado, Kansas, Michigan, Minnesota, New York, Ohio
2026-01-26
Recruiting
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
NCT07263594Gastrointestinal Cancer
DualityBio Inc.
Phase 1/2
127
Florida, Michigan, North Carolina, Ohio
2026-01-20
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
NCT07359846Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
California, Florida, Massachusetts, Michigan, New York, Ohio, Oklahoma, South Carolina
2026-01-20
Recruiting
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
NCT07114718Congenital Heart Disease, Congenital Heart Disease (CHD)
Starlight Cardiovascular Inc
Not applicable
45
California, Colorado, Massachusetts, Ohio, Pennsylvania, Texas, Washington
2026-01-16
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT07319871Prostatic Neoplasms
DrugsJNJ-86974680·Pasritamig
Janssen Research & Development, LLC
Phase 1
40
Florida, New York, Ohio
2026-01-14
Active, closed
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
NCT07298330Chronic Hepatitis D Infection
DrugBulevirtide
Mirum Pharmaceuticals, Inc.
Phase 3
80
California, Colorado, Nevada, Ohio, Texas, Utah
2026-01-14
Recruiting
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07089121Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
DrugDescartes-08
Cartesian Therapeutics
Phase 1/2
50
District of Columbia, Missouri, Ohio
2026-01-14
Recruiting
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
NCT07006688IDH1-Mutated Malignancies
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 1
30
Georgia, Ohio, Texas
2026-01-14
Recruiting
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
NCT07049055Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsNab-paclitaxel·Gemcitabine
Engeneic Pty Limited
Phase 1/2
144
California, New Jersey, New York, Ohio
2026-01-12
Recruiting
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07290062Amyotrophic Lateral Sclerosis
Insmed Gene Therapy LLC
Phase 1
23
California, Maryland, Massachusetts, Missouri, Ohio, Pennsylvania
2026-01-09
Recruiting
Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy
NCT07675200Autophagy, Healthy Aging
Nutraland USA, Inc.
Not applicable
70
Ohio
2026-01-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454Depressive Disorder, Major
DrugsEsketamine·Midazolam
Janssen Research & Development, LLC
Phase 3
258
Alabama, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota, Ohio
2026-01-08
Recruiting
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
NCT06904261Fabry Disease
DrugMigalastat HCl
Amicus Therapeutics
Phase 3
8
Georgia, Minnesota, North Carolina, Ohio, Pennsylvania, Virginia
2026-01-08
Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380Pulmonary Hypertension, Interstitial Lung Disease
DrugTreprostinil Palmitil
Insmed Incorporated
Phase 3
344
Arizona, California, Florida, Kansas, New York, North Carolina, Ohio, Oregon
2026-01-07
Recruiting
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
NCT07187973Sickle Cell Disease
DrugDISC-3405
Disc Medicine, Inc
Phase 1
24
Alabama, California, Georgia, Illinois, Indiana, New York, North Carolina, Ohio
2026-01-06
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761Relapsed and/or Refractory Multiple Myeloma (RRMM)
DrugsLinvoseltamab·Darzalex·Velcade·Carfilzomib
Regeneron Pharmaceuticals
Phase 3
915
Georgia, New York, Ohio, Texas
2026-01-02
Recruiting
Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
NCT07182058PARKINSON DISEASE (Disorder)
U: The Mind Company
Phase 1/2
30
Ohio
2026-01-01
Recruiting
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT07351071Colorectal Anastomosis, Left-sided Colon Resection, Anastomotic Leak, Anastomotic Complication
Medtronic - MITG
Not applicable
137
Connecticut, Florida, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania
2025-12-30
Recruiting
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
NCT07223229Non-segmental Vitiligo
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2
45
California, Florida, Massachusetts, Ohio, Texas
2025-12-30
Recruiting
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
NCT07399678Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
DrugALV-100
Alveus Therapeutics, Inc.
Phase 1
180
Florida, Ohio, Texas
2025-12-29
Recruiting
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
NCT07400952Keratoconus
Glaukos Corporation
Phase 2
100
Ohio
2025-12-23
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
Neomorph, Inc
Phase 1
30
California, Connecticut, Florida, Illinois, Michigan, Nebraska, New York, Ohio
2025-12-19
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis
DrugsEmpasiprubart·Efgartigimod
argenx
Observational
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Active, closed
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686Obesity, Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-12-19
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
DrugsEmpasiprubart·Efgartigimod
argenx
Phase 2
70
California, Florida, Massachusetts, Michigan, Nevada, New York, North Carolina, Ohio
2025-12-19
Recruiting
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
NCT07305818Graves Disease
Merida Biosciences
Phase 1
100
California, Florida, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania, Texas
2025-12-19
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Arkansas, California, Illinois, Michigan, New Jersey, New York, Ohio, Texas
2025-12-19
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Indiana, New York, Ohio, Oregon, Texas
2025-12-17
Recruiting
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
NCT07228247Solid Tumors, Adult
Hutchmed
Phase 1/2
147
Colorado, Florida, New Jersey, New York, Ohio, Washington
2025-12-16
Recruiting
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
NCT07219407Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
DrugRAP-219
Rapport Therapeutics Inc.
Phase 2
30
Idaho, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-12-15
Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588Osteogenesis Imperfecta (OI)
DrugAGA2115
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474Squamous Non-small Cell Lung Cancer
DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
NCT07214571Respiratory Syncytial Virus Infections
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Active, closed
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403Short Bowel Syndrome (SBS)
DrugGlepaglutide
Zealand Pharma
Phase 3
28
Minnesota, Nebraska, Ohio, Tennessee
2025-12-11
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07217717Pancreatic Ductal Adenocarcinoma (PDAC)
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-12-11
Recruiting
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
NCT07172893Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
HealthTech Wound Care
Phase 4
150
Florida, Michigan, North Carolina, Ohio, Texas, Virginia
2025-12-10
Recruiting
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
NCT06910943Choline Deficiency, Liver Injury
Protara Therapeutics
Phase 2/3
129
Colorado, Florida, Illinois, Nebraska, New York, North Carolina, Ohio, Texas
2025-12-10
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Missouri, New York, Ohio, Washington, Wisconsin
2025-12-09
Recruiting
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999Small Cell Lung Cancer (SCLC)
DrugsPF-08634404·Atezolizumab
Pfizer
Phase 2/3
550
Arkansas, Florida, Ohio, Texas, Virginia
2025-12-09
Active, closed
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
NCT07700433Back Pain
BTL Industries Ltd.
Not applicable
60
Arizona, Florida, Ohio, Texas
2025-12-08
Recruiting
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
NCT07249463Cryptosporidiosis
Novartis Pharmaceuticals
Phase 2
80
Maryland, Ohio
2025-12-08
Active, closed
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
51
California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington
2025-12-08
Recruiting
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598Rheumatoid Arthritis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
160
Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Ohio
2025-12-05
Active, closed
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
NCT07222917Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 2
222
Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania
2025-12-05
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
110
California, Florida, Illinois, Ohio, South Carolina, Texas, Wisconsin
2025-12-04
Recruiting
Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers
NCT07161830Diabetic Foot Ulcer
Omeza, LLC
Not applicable
180
Illinois, Louisiana, Mississippi, Ohio
2025-12-04
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
RayzeBio, Inc.
Phase 1
104
Arizona, Florida, Iowa, Kentucky, Minnesota, Missouri, Ohio, Oregon
2025-12-03
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Active, closed
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
58
Alabama, California, Missouri, Ohio, South Carolina, Tennessee, Texas
2025-12-01
Recruiting
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
NCT07281599HPV Infection, HPV 16 Infection, High Risk HPV, Cervical Cancer Screening
Qurasense
Not applicable
450
Connecticut, Minnesota, Ohio
2025-12-01
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
DrugsPF-08634404·Yervoy·Ipilimumab
Pfizer
Phase 1/2
138
California, Florida, Illinois, Minnesota, Missouri, Nevada, North Carolina, Ohio
2025-12-01
Recruiting
Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes
NCT07222787Radiculopathy Lumbar, Degenerative Lumbar Disc Disease
Providence Medical Technology, Inc.
Not applicable
250
Arizona, California, Illinois, New York, North Carolina, Ohio, Texas, Utah
2025-12-01
Not yet open
Swivel Convertible Child Safety Seat to Improve Usage
NCT06866171Motor Vehicle Injury
Minnesota HealthSolutions
Observational
100
Ohio
2025-12
Recruiting
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625Acromegaly
Debiopharm International SA
Phase 3
119
California, Illinois, Massachusetts, Missouri, Nevada, New York, Ohio, Oregon
2025-11-26
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab
AbbVie
Phase 2
180
Connecticut, Florida, Indiana, Kentucky, Massachusetts, Michigan, Missouri, Ohio
2025-11-25
Active, closed
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Arizona, California, Florida, Maryland, Michigan, Minnesota, Ohio, Rhode Island
2025-11-24
Recruiting
A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults
NCT07444294Healthy
Scholar Rock, Inc.
Phase 1
76
Ohio
2025-11-21
Recruiting
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
DrugDarolutamide
K36 Therapeutics, Inc.
Phase 1
144
California, Florida, Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2025-11-21
Recruiting
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027Atopic Dermatitis, Eczema, Atopic
Pfizer
Phase 2
165
Arizona, California, Florida, New York, Ohio, Pennsylvania
2025-11-20
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
223
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448Colorectal Cancer
DrugsONO-4578·Leucovorin·Opdivo·Adrucil
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.
Phase 1/2
27
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Pennsylvania
2025-11-18
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Alabama, California, Florida, Michigan, Ohio, Oklahoma
2025-11-14
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-11-14
Recruiting
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07095465Lewy Body Dementia Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 3
126
California, Florida, Hawaii, Kansas, New York, Ohio, Oklahoma, Texas
2025-11-14
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
NCT07223138Arthritis, Psoriatic
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
1,560
Arizona, Arkansas, California, Florida, North Carolina, Ohio, Pennsylvania, Tennessee
2025-11-13
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Recruiting
Actinium Therapy for Late-stage Aggressive Sarcomas
NCT07156565Advanced Soft Tissue Sarcoma
Ratio Therapeutics, Inc.
Phase 1
48
California, Minnesota, New York, Ohio, Texas
2025-11-12
Recruiting
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)
NCT07216872Alcohol Use Disorder, Alcoholism, Alcohol Abuse, Alcohol Dependence
Brainsway
Not applicable
186
Alabama, California, Florida, Illinois, New York, Ohio, Oregon, West Virginia
2025-11-07
Recruiting
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
NCT07220876Open Angle Glaucoma (OAG)
Avisi Technologies Inc.
Not applicable
165
Arizona, California, Colorado, Ohio, Pennsylvania, Texas, Wisconsin
2025-11-07
Active, closed
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
NCT07187115Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Boston Scientific Corporation
Not applicable
699
Arkansas, California, Georgia, Idaho, New York, Ohio, Pennsylvania, Texas
2025-11-07
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Recruiting
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
NCT07219589Obesity, Obese
Hanmi Pharmaceutical Company Limited
Phase 1
90
Ohio
2025-11-06
Recruiting
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
NCT07203001Still´s Disease
DrugArumakimig
Novartis Pharmaceuticals
Phase 2
30
Ohio, Oregon, Utah
2025-11-03
Recruiting
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283Nonsegmental Vitiligo
DrugZasocitinib
Takeda
Phase 2
200
Arkansas, California, Florida, Louisiana, Maryland, Michigan, New York, Ohio
2025-11-03
Recruiting
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
NCT07098858Heart Failure
EBR Systems, Inc.
Observational
320
Arizona, Arkansas, Florida, Michigan, Missouri, New York, Ohio, Pennsylvania
2025-11-03
Recruiting
Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri/Post-Menopausal Women
NCT07402382Glucose Monitoring, Continuous, Whole Body Protein Metabolism, Peri-menopausal Women, Post-menopause
Nutrition 21, Inc.
Not applicable
60
Ohio
2025-11-01
Recruiting
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
NCT07123155Pompe Disease
Shionogi
Phase 2
45
California, Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Virginia
2025-10-30
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-10-27
By invitation
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
NCT06986447Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
HRI-MAIL-NIT
Observational
1,689
Arizona, Ohio, Texas
2025-10-25
Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT07218887BAG3 Mutation Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 1/2
6
Alabama, California, Massachusetts, Ohio, Oregon, Pennsylvania, Texas
2025-10-24
By invitation
Pilot Trial of Mobile Technology for Adolescent Suicidality
NCT06454136Suicidal Ideation
Oui Therapeutics, Inc.
Not applicable
228
Connecticut, Ohio, Rhode Island
2025-10-23
Active, closed
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
NCT07223216Obesity
Biomea Fusion Inc.
Phase 1
80
Ohio
2025-10-23
Recruiting
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
NCT07180355Friedreich's Ataxia (FA)
Solid Biosciences Inc.
Phase 1
10
California, Ohio, Pennsylvania
2025-10-22
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Florida, Indiana, Kansas, Maryland, Michigan, New York, North Carolina, Ohio
2025-10-20
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609Neoplasms, Colorectal, Neoplasms
GlaxoSmithKline
Phase 1/2
47
Colorado, Michigan, Ohio, Tennessee
2025-10-20
Recruiting
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
DrugLuxdegalutamide
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Recruiting
Z1 Hip System: Post-Market Clinical Follow Up Study
NCT07104279Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck, Avascular Necrosis of the Femoral Head
Zimmer Biomet
Observational
300
North Carolina, Ohio, Oregon, Virginia
2025-10-13
Active, closed
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 2
60
California, Illinois, Maryland, Missouri, North Carolina, Ohio, Texas
2025-10-13
Recruiting
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
NCT07205926Shigella, Diarrhea
Inventprise Inc.
Phase 1
60
Ohio
2025-10-09
Recruiting
FebriDx® Pediatric Validation Study
NCT07211997Acute Respiratory Infections (ARIs)
Lumos Diagnostics
Observational
800
California, Florida, Ohio, Pennsylvania, South Carolina, Texas
2025-10-09
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
140
Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington
2025-10-09
Recruiting
Fluid Guided Heart Failure Treatment at the Cleveland Clinic
NCT07205120Heart Failure
Bodyport Inc.
Not applicable
50
Ohio
2025-10-08
Recruiting
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
NCT07140900Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
DrugsXaluritamig·Abiraterone·Darolutamide
Amgen
Phase 1
60
California, Massachusetts, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2025-10-07
Active, closed
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT07219121Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
DrugSparsentan
Travere Therapeutics, Inc.
Phase 4
20
Alabama, New York, North Carolina, Ohio, Texas, Washington, Wisconsin
2025-10-07
Recruiting
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
NCT07149857Multiple Myeloma
DrugsCilta-cel·Fludarabine·Cyclophosphamide
Janssen Research & Development, LLC
Phase 2
60
California, Florida, Iowa, New York, North Carolina, Ohio
2025-10-03
Recruiting
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
NCT07193511Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
Avenzo Therapeutics, Inc.
Phase 1/2
355
California, Colorado, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2025-10-02
Active, closed
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
DrugNeflamapimod
EIP Pharma Inc
Phase 2
20
Illinois, Minnesota, New York, Ohio, Pennsylvania
2025-10-02
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908NSCLC Stage IV
DrugsTislelizumab·Docetaxel
ImmunityBio, Inc.
Phase 3
507
Arkansas, California, Florida, Georgia, Missouri, North Carolina, Ohio, South Carolina
2025-10-01
By invitation
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
NCT07204938Hereditary Angioedema (HAE)
DrugNavenibart
Astria Therapeutics, Inc.
Phase 3
145
Arizona, Arkansas, California, Colorado, Maryland, Ohio, Pennsylvania
2025-10-01
Recruiting
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.
Phase 2
40
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, Ohio
2025-10-01
Recruiting
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
NCT06910306Recurrent Glioblastoma, Recurrent Gliomas
Alpha Tau Medical LTD.
Not applicable
10
Arizona, New York, Ohio
2025-10-01
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
710
Florida, Indiana, Louisiana, North Carolina, Ohio, South Dakota, Texas
2025-09-30
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio, Oregon
2025-09-30
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
DrugRilzabrutinib
Sanofi
Phase 3
124
California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2025-09-26
Recruiting
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
NCT06441331Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor
Drug177Lu-edotreotide
ITM Solucin GmbH
Phase 1
20
California, Ohio, Pennsylvania, Texas
2025-09-26
Active, closed
SPHERE Per-AF Post-Approval Study
NCT06858306Persistent Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alabama, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania
2025-09-25
Recruiting
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
NCT07185256ARB, BVMD, Autosomal-Dominant Bestrophinopathy, Best Vitelliform Macular Dystrophy
Opus Genetics, Inc
Phase 1/2
10
California, Florida, New York, Ohio, Texas
2025-09-25
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
California, Florida, Minnesota, New York, Ohio, South Carolina, Tennessee
2025-09-24
Recruiting
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
NCT06751238Juvenile Psoriatic Arthritis
DrugSecukinumab
Novartis Pharmaceuticals
Phase 1
20
California, Florida, Illinois, New York, North Carolina, Ohio, Oregon, Pennsylvania
2025-09-24
Recruiting
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
NCT06941870Factor VIII Deficiency
DrugEfanesoctocog alfa
Sanofi
Phase 4
35
California, Indiana, Iowa, Ohio
2025-09-23
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
DrugsBNT326·Pumitamig
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Recruiting
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
NCT06725030Open Surgery, Lymphedema, Free Tissue Transfer, Microsurgery
MMI (Medical Microinstruments, Inc.)
Observational
455
California, Connecticut, Florida, New York, Ohio
2025-09-22
By invitation
Ovolux Beauty From Within Trial#2
NCT07188051Skin Sagging, Skin Wrinkling, Skin Dryness
ESM Technologies, LLC
Not applicable
100
Ohio
2025-09-22
Active, closed
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797Non-Small Cell Lung Cancer
DrugsNivolumab and rHuPH20·Yervoy·Ipilimumab·Pemetrexed
Bristol-Myers Squibb
Phase 2
76
Alaska, California, Idaho, Ohio, Pennsylvania
2025-09-19
Recruiting
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
NCT07015437Healthy Subjects
Cerus Corporation
Phase 2
120
Ohio, Virginia
2025-09-19
Recruiting
Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
NCT07228026Asthma
Biometry Inc
Observational
160
California, Florida, Georgia, Maine, Maryland, Nebraska, North Carolina, Ohio
2025-09-17
Recruiting
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
NCT07207707Solid Tumor Malignancies
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
Technology Assisted Treatment of Trichotillomania: Open Trial
NCT07224126Trichotillomania
HabitAware Inc.
Not applicable
10
Ohio
2025-09-15
Recruiting
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
NCT07094087Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring
Phase 3
200
California, Georgia, Illinois, Kansas, Maryland, New Jersey, New York, Ohio
2025-09-15
Active, closed
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
NCT07207408Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
Dynavax Technologies Corporation
Phase 2
148
Florida, Kansas, Nevada, Ohio
2025-09-11
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
DrugDelgocitinib
LEO Pharma
Phase 2
135
California, Georgia, Michigan, New York, Ohio, Oregon, Pennsylvania
2025-09-11
Active, closed
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
NCT07174726X-Linked Retinitis Pigmentosa (XLRP)
Beacon Therapeutics
Phase 2
10
Florida, North Carolina, Ohio, Oregon, Texas
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsNavlimetostat·Iza-bren
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
NCT07060716Kidney Transplant Rejection, Cell-free DNA
Insight Molecular Diagnostics
Observational
125
California, Florida, Ohio, Pennsylvania, Tennessee, Texas, Utah
2025-09-08
By invitation
AB-1005 Long-Term Follow-up Study
NCT07081841Parkinson's Disease, Multiple System Atrophy, Parkinson Variant
AskBio Inc
Observational
132
California, Ohio
2025-09-04
By invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
DrugGlyphAllo
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
DrugValbenazine
Neurocrine Biosciences
Phase 4
100
Arkansas, California, Florida, Georgia, Illinois, Nebraska, Ohio, Texas
2025-08-29
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Florida, Iowa, Louisiana, Michigan, New York, Ohio, South Dakota, Texas
2025-08-28
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Not yet open
Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
NCT07118449Coronary Artery Disease (CAD)
XyloCor Therapeutics, Inc.
Phase 2
116
Ohio
2025-08-27
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
SLV-324 Treatment of Metastatic Solid Tumors
NCT07108114Metastatic Solid Tumors
Solve Therapeutics
Phase 1
70
California, Missouri, Ohio, Pennsylvania, Texas, Washington
2025-08-25
Recruiting
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
NCT06830863EGFR Inhibitor-associated Rash
Azitra Inc.
Phase 1/2
32
Arkansas, Connecticut, New York, Ohio, Texas, Virginia
2025-08-25
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
DrugBHV-1300
Biohaven Therapeutics Ltd.
Phase 1
15
California, Florida, Georgia, North Carolina, Ohio, Tennessee, Texas
2025-08-21
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Recruiting
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
NCT06998407HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
DrugsAVZO-021·Letrozole·Fulvestrant
Avenzo Therapeutics, Inc.
Phase 1/2
380
California, Connecticut, Florida, Massachusetts, New York, Ohio, Tennessee, Texas
2025-08-20
By invitation
An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
NCT06867107Duchenne Muscular Dystrophy (DMD)
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
30
California, Ohio, Tennessee
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Alabama, California, Florida, Illinois, Louisiana, New Mexico, Ohio, South Carolina
2025-08-19
Recruiting
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485Non Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 2
40
California, Florida, Michigan, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2025-08-18
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
California, Florida, Michigan, New Jersey, Ohio, Oregon, Texas, Utah
2025-08-18
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
California, Colorado, Georgia, Massachusetts, New York, Ohio, Pennsylvania, Texas
2025-08-18
Recruiting
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
NCT07049328Alopecia Areata(AA)
HCW Biologics
Phase 1
30
Florida, Indiana, Ohio
2025-08-16
Recruiting
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
NCT07019922Epileptic Encephalopathy, SCN2A Encephalopathy
Praxis Precision Medicines
Phase 3
40
California, Colorado, Illinois, Ohio, Pennsylvania, Tennessee
2025-08-13
Recruiting
The DistaSense VITALS Study
NCT07217327Detection of Heart Rate and Respiratory Rate
Life Detection Technologies
Observational
20
Missouri, Ohio
2025-08-13
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
90
Alabama, California, Florida, Georgia, Michigan, Nevada, North Carolina, Ohio
2025-08-12
Recruiting
Janus II Feasibility
NCT06556693Sleep Apnea
Zoll Medical Corporation
Not applicable
40
Arizona, Michigan, Ohio
2025-08-12
Active, closed
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
NCT06985147Polycythemia Vera (PV)
DrugDISC-3405
Disc Medicine, Inc
Phase 2
60
Arizona, California, Florida, Minnesota, Missouri, North Carolina, Ohio, Oregon
2025-08-12
Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596Malignant Neoplasm
DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole
Merck Sharp & Dohme LLC
Phase 2
250
Alaska, Florida, Louisiana, Nebraska, New Jersey, New York, Ohio, Texas
2025-08-11
Recruiting
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098Schizophrenia
DrugNBI-1117568
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Ohio
2025-08-11
Recruiting
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
NCT07122986Healthy Participants
Pfizer
Phase 1
310
California, Florida, New York, Ohio, Tennessee
2025-08-11
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898Neoplasms, Lung
DrugsRis-Rez·Risvutatug rezetecan·Topotecan
GlaxoSmithKline
Phase 3
420
California, New York, North Carolina, Ohio
2025-08-11
Recruiting
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
NCT02880163Hemorrhagic Shock, Trauma, Exsanguinating Hemorrhage, Shock; Traumatic
Arsenal Medical, Inc.
Not applicable
40
Alabama, Ohio
2025-08-07
Recruiting
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
NCT07158918Solid Tumors
DrugsABL103·Keytruda·Pembrolizumab
ABL Bio, Inc.
Phase 1/2
65
Ohio
2025-08-06
Active, closed
Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage
NCT06655207Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Baymatob Operations Pty Ltd
Not applicable
1,000
Colorado, Louisiana, New York, Ohio, Pennsylvania
2025-08-06
Recruiting
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Lantheus Medical Imaging
Phase 1/2
26
California, Michigan, Ohio
2025-08
Recruiting
Evaluate the Effects of Citicoline on Mood in Healthy Adults
NCT07089238Healthy
Kirin Holdings Company, Limited
Not applicable
90
Ohio
2025-07-31
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
NCT07024784Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
DrugsIMGN151·Olaparib·Bevacizumab·Carboplatin
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
NCT06328608Fabry Disease
Chiesi Farmaceutici S.p.A.
Phase 2/3
22
Arizona, Georgia, Iowa, Ohio, Utah, Virginia
2025-07-29
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
DrugRisankizumab
AbbVie
Phase 3
120
Arizona, California, Florida, Georgia, Illinois, New Jersey, Ohio, Pennsylvania
2025-07-28
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244Acute Ischemic Stroke, Cerebral Stroke
DrugSovateltide
Pharmazz, Inc.
Phase 3
514
Arizona, California, Florida, Georgia, Missouri, New Jersey, North Carolina, Ohio
2025-07-24
Recruiting
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
NCT07406282Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer
DrugsApalutamide·Abiraterone acetate·Darolutamide·Enzalutamide
Bayer
Observational
1,400
Ohio
2025-07-22
Active, closed
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT07086677Streptococcus Pneumoniae
DrugPrevnar 20
Pfizer
Phase 1
380
California, Florida, Kansas, Missouri, Nebraska, New York, North Carolina, Ohio
2025-07-22
Active, closed
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT06817382Duchenne Muscular Dystrophy
Insmed Gene Therapy LLC
Phase 1
12
Arkansas, California, Georgia, New York, Ohio, Tennessee, Virginia
2025-07-22
Recruiting
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
NCT06888921Ovarian Cancer, Ovarian Cancer Recurrent
Compugen Ltd
Phase 1/2
60
Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina, Ohio, Oklahoma
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
California, District of Columbia, Kansas, Maryland, Missouri, New York, North Carolina, Ohio
2025-07-18
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT07079631Metastatic Colorectal Cancer
DrugsBNT314·Pumitamig·Bevacizumab
BioNTech SE
Phase 1/2
482
Connecticut, Michigan, Ohio, Texas
2025-07-18
Recruiting
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
NCT07015697Recurrent or Metastatic Solid Tumors
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 1
76
California, Georgia, Nevada, North Carolina, Ohio, Tennessee
2025-07-17
Active, closed
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
NCT07106021Idiopathic Parkinson´s Disease, Parkinson&#39;s Disease
Kenai Therapeutics
Phase 1/2
12
Arizona, California, Ohio
2025-07-17
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Arizona, Colorado, Florida, Louisiana, Massachusetts, Minnesota, New York, Ohio
2025-07-16
Recruiting
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
NCT07017933Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury
3ive Labs
Not applicable
124
Florida, Michigan, North Carolina, Ohio
2025-07-16
Active, closed
Comparison of Pharmacokinetic Responses to Three Ketone Esters
NCT07289165Healthy Volunteer
NeuroEnergy Ventures, Inc.
Not applicable
18
Ohio
2025-07-15
Recruiting
A Study to Evaluate the SENSE Device's Ability to Detect TBI
NCT06828107Traumatic Brain Injury
Sense Diagnostics, LLC
Observational
150
Florida, Ohio, Pennsylvania, South Carolina, Texas
2025-07-11
Active, closed
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384HIV Infections
DrugsVH3810109·Fostemsavir
ViiV Healthcare
Phase 1
107
California, Florida, Illinois, Missouri, New York, Ohio, Pennsylvania, Texas
2025-07-10
Recruiting
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
NCT06927999Urticaria Chronic
DrugEpinephrine
ARS Pharmaceuticals, Inc.
Phase 2
42
Illinois, Ohio
2025-07-09
Recruiting
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT07082920Prostatic Neoplasms
DrugsARX517·JNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 1
140
Florida, New York, Ohio, Washington
2025-07-07
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
DrugBevacizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
NCT06892522Multiple Myeloma
DrugsMezigdomide·Etentamig·Iberdomide·Carfilzomib
AbbVie
Phase 1/2
602
California, Colorado, Florida, Georgia, New York, North Carolina, Ohio, Texas
2025-06-30
Recruiting
A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function
NCT06993155Semen Quality
DrugLeflutrozole, 2
ReproNovo Aps
Phase 2
200
California, New York, Ohio
2025-06-27
Recruiting
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
NCT06935591Atrial Fibrillation (AF)
Vektor Medical
Not applicable
423
Arkansas, Florida, Georgia, Indiana, Kentucky, New York, Ohio, Pennsylvania
2025-06-27
Recruiting
Prospective, Open-label, Non-significant Risk, Multicenter Study Comparing the Polyp Detection of the Study Device to That of the Colonoscopy Reference
NCT07089615Colonic Polyps
Capso Vision, Inc.
Not applicable
330
California, Florida, Illinois, New York, Ohio
2025-06-26
Recruiting
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NCT07033026Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
NGM Biopharmaceuticals, Inc
Phase 2
136
California, Florida, Maryland, New York, Ohio, Texas, Virginia, Wisconsin
2025-06-25
Recruiting
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06994806Solid Tumor Malignancies
DrugPembrolizumab
Kumquat Biosciences Inc.
Phase 1
84
Arizona, California, Colorado, Connecticut, Florida, Iowa, Minnesota, Ohio
2025-06-24
Recruiting
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
NCT06464926Nausea, Vomiting
Enterra Medical, Inc.
Not applicable
148
Arizona, California, Florida, Illinois, Indiana, Kentucky, New Jersey, Ohio
2025-06-23
Recruiting
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
NCT07016750Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc.
Phase 3
16
California, Florida, Massachusetts, Ohio, Texas
2025-06-20
Active, closed
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
NCT06736990Idiopathic Pulmonary Fibrosis
Calluna Pharma AS
Phase 2
150
California, Colorado, Florida, Kansas, North Carolina, Ohio, Pennsylvania, Utah
2025-06-20
Recruiting
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
NCT06872684Aneurysm, Aneurysm, Intracranial
Stryker Neurovascular
Not applicable
183
Arizona, California, Florida, Kansas, Massachusetts, New York, Ohio, Oregon
2025-06-20
Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
DrugGlyphAllo
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-06-19
Recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257Heart Failure
DrugPF-07328948
Pfizer
Phase 2
620
California, Florida, Illinois, Indiana, Maryland, Nebraska, Ohio, Texas
2025-06-19
Active, closed
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
NCT07037771Homozygous Familial Hypercholesterolemia
DrugZodasiran
Arrowhead Pharmaceuticals
Phase 3
70
Illinois, New York, Ohio, Pennsylvania
2025-06-17
Recruiting
AERA Pediatrics Registry
NCT07071298Dysfunction of Eustachian Tube
Integra LifeSciences Corporation
Observational
300
California, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Texas, Utah
2025-06-17
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
DrugIMG-007
Inmagene LLC
Phase 2
405
California, Florida, Illinois, New York, North Carolina, North Dakota, Ohio, Oregon
2025-06-17
Active, closed
AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair
NCT06710795Ventral Hernia
Medtronic - MITG
Not applicable
35
Florida, Ohio
2025-06-16
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
NCT06951698Bipolar-I Disorder With Mania or Mania With Mixed Features
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Connecticut, Florida, Georgia, Illinois, New York, Ohio
2025-06-11
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
DrugsDoxorubicin·Docetaxel·Paclitaxel
BioNTech SE
Phase 3
480
Connecticut, District of Columbia, Florida, Illinois, Louisiana, Nevada, New York, Ohio
2025-06-10
Recruiting
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
NCT06971614Nonmuscle-invasive Bladder Cancer
DrugT3011
ImmVira Pharma Co. Ltd
Phase 2
160
Arizona, California, Florida, New Jersey, Ohio, Pennsylvania, South Carolina
2025-06-09
Active, closed
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984Chikungunya Virus
Bavarian Nordic
Phase 3
720
California, District of Columbia, Florida, Nebraska, Ohio, Texas, Utah
2025-06-05
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867Myelodysplastic Syndromes
DrugMomelotinib
GlaxoSmithKline
Phase 2
80
Arizona, California, Connecticut, Ohio, Texas
2025-06-05
Active, closed
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
NCT06672978Acute Pyelonephritis, Complicated Urinary Tract Infection
DrugMeropenem-Vaborbactam
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Phase 2
66
Arkansas, California, Nebraska, Ohio
2025-06-03
Recruiting
Evaluation of Cochlear (Promontory) Stimulation During Awake Ear Surgery (TONES Study)
NCT07402941Hearing Disorder
Auricle Health Inc.
Not applicable
18
Ohio
2025-06-02
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
Arizona, California, District of Columbia, Florida, Massachusetts, New Jersey, New York, Ohio
2025-06-01
Recruiting
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease
NCT06872905Aortoiliac Occlusive Disease
W.L.Gore & Associates
Observational
158
California, Florida, Minnesota, New Jersey, New York, North Carolina, Ohio, Pennsylvania
2025-05-30
Recruiting
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
NCT06969430Acute Myeloid Leukemia
Debiopharm International SA
Phase 1/2
154
California, Florida, Illinois, Michigan, New York, Ohio, Texas
2025-05-30
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Vironexis Biotherapeutics Inc.
Phase 1/2
32
California, Colorado, Florida, Minnesota, New York, North Carolina, Ohio, Oregon
2025-05-30
Active, closed
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
NCT07023731KRAS G12D Mutation, Advanced Solid Cancer
Arvinas Inc.
Phase 1/2
76
Arizona, Connecticut, Florida, Indiana, Michigan, New York, North Carolina, Ohio
2025-05-29
Recruiting
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
NCT06973564Advanced Solid Tumors
DrugJAB-23E73
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
294
Minnesota, Missouri, Ohio, Utah
2025-05-29
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Arizona, Massachusetts, Minnesota, New York, Ohio, Texas, Utah, Washington
2025-05-28
Recruiting
STimulation to Activate RespIration
NCT06832306ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients
Lungpacer Medical Inc.
Not applicable
30
California, Louisiana, North Carolina, Ohio, Pennsylvania, South Carolina
2025-05-28
Active, closed
A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot
NCT06879912Hernia, Inguinal, Hernia, Ventral, Colorectal, Thoracic
Intuitive Surgical
Observational
200
California, Florida, Georgia, Illinois, Ohio, Texas
2025-05-24
Recruiting
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Washington
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas
2025-05-22
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301Advanced Melanoma
DrugsEIK1001·Keytruda·Pembrolizumab
Eikon Therapeutics
Phase 2/3
740
Arizona, Arkansas, California, Colorado, Florida, Maryland, Missouri, Ohio
2025-05-22
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
California, Florida, Idaho, Maryland, Michigan, Nevada, New York, Ohio
2025-05-21
Recruiting
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
NCT06834165Allergic Reactions
DrugAdrenaline
ARS Pharmaceuticals, Inc.
Phase 4
600
California, District of Columbia, Illinois, Michigan, New York, Ohio
2025-05-20
Recruiting
A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition
NCT06581146X-Linked Myotubular Myopathy
Astellas Gene Therapies
Observational
50
California, Illinois, Massachusetts, Ohio, Pennsylvania, Utah
2025-05-19
Recruiting
A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)
NCT06968741Stress Urinary Incontinence (SUI)
UroMems SAS
Not applicable
140
California, Minnesota, North Carolina, Ohio, Tennessee, Texas, Virginia
2025-05-19
Active, closed
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957Small Cell Lung Cancer
DrugsTam-Peli·Tarlatamab·Durvalumab
Amgen
Phase 1
29
California, Connecticut, Florida, Massachusetts, Missouri, North Dakota, Ohio, South Dakota
2025-05-16
Recruiting
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
NCT06995729Acute Treatment of Migraine
Pfizer
Phase 1
16
District of Columbia, Georgia, Minnesota, Nebraska, New York, North Carolina, Ohio, Oklahoma
2025-05-16
Active, closed
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
NCT06859970Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
InterShunt Technologies, Inc.
Not applicable
20
Arkansas, California, Indiana, Ohio, Texas
2025-05-15
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397Fabry Disesase
GC Biopharma Corp
Phase 1/2
18
California, Kansas, Minnesota, Ohio, Pennsylvania, Virginia
2025-05-14
Active, closed
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852Head and Neck Squamous Cell Carcinoma
DrugsBI 770371·Cetuximab·Pembrolizumab
Boehringer Ingelheim
Phase 1
91
Kentucky, Minnesota, Ohio
2025-05-14
Active, closed
A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults
NCT06967181Mumps
CyanVac LLC
Phase 1
60
New York, Ohio, South Carolina
2025-05-14
Active, closed
PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System
NCT06133387Colorectal Lesion, Colorectal Adenoma, Colorectal Polyp, Rectal Lesion
EndoQuest Robotics, Inc.
Not applicable
56
Arizona, Florida, Massachusetts, Ohio, Texas
2025-05-13
Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281Solid Tumors
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
NCT06662162Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
Not applicable
100
California, Connecticut, Illinois, Nevada, Ohio, Texas
2025-05-07
Recruiting
DEVELOPMENT OF A NOVEL PEER RECOVERY SUPPORTER TRAINING PLATFORM
NCT07044531Substance Use Disorders, Alcohol Use Disorders, Recovery Support Services, Peer Recovery Coaching
Thrive Digital Health, LLC
Not applicable
450
Ohio
2025-05-07
Recruiting
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT06680037B-cell Mediated Autoimmune Disorders
DrugAzer-cel
TG Therapeutics, Inc.
Phase 1
100
California, Michigan, Nebraska, New York, Ohio, Wisconsin
2025-05-06
Recruiting
Safety of HRX215 in Patients After Minor and Major Liver Resection
NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases
HepaRegeniX GmbH
Phase 1/2
80
Maryland, Minnesota, North Carolina, Ohio
2025-05-06
Recruiting
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06747351Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
DrugsTAK-881·Phesgo
Takeda
Phase 3
59
Arizona, California, Connecticut, Florida, Missouri, New York, North Carolina, Ohio
2025-05-06
Recruiting
Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array
NCT06936449Sensorineural Hearing Loss, Bilateral Hearing Loss
Cochlear
Observational
19
Colorado, Iowa, Ohio
2025-05-05
Active, closed
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity
DrugsRO7204239·Tirzepatide
Hoffmann-La Roche
Phase 2
285
Alabama, California, Florida, Georgia, Illinois, New York, North Carolina, Ohio
2025-05-05
Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes
Auron Therapeutics, Inc.
Phase 1
69
California, Florida, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
2025-05-01
Recruiting
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases
DrugsAnitocabtagene Autoleucel·Fludarabine·Cyclophosphamide
Arcellx, Inc.
Phase 1
30
California, Florida, Michigan, Minnesota, New York, Ohio, Oregon, Pennsylvania
2025-04-30
Active, closed
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
NCT06544330Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
DrugsSTK-009·SYNCAR-001
Synthekine
Phase 1
48
Arizona, New Jersey, New York, Ohio
2025-04-29
Recruiting
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
NCT06746883Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Innoviva Specialty Therapeutics
Observational
100
California, Florida, Kansas, Kentucky, Louisiana, New York, Ohio, Pennsylvania
2025-04-28
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, Ohio, Pennsylvania
2025-04-28
Recruiting
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
NCT06533761AML, Adult, MDS
DrugCytarabine
Stelexis BioSciences
Phase 1
125
California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio, Texas
2025-04-28
Recruiting
Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries
NCT06867185Digital Nerve Injury, Nerve Injury, Nerve Reconstruction, Nerve Trauma
Checkpoint Surgical Inc.
Not applicable
60
Indiana, Missouri, Ohio, Washington
2025-04-24
Recruiting
Pivotal Study for the Cardiac Performance System (CPS)
NCT06870591Cardiovascular Diseases
Sensydia Corporation
Observational
1,000
Alabama, Illinois, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Tennessee
2025-04-22
By invitation
An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2/3
24
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2025-04-22
Recruiting
Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone
NCT06777901Peripheral Arterial Diseases
Angiodynamics, Inc.
Phase 4
224
Arizona, California, Louisiana, Maryland, Massachusetts, Missouri, North Carolina, Ohio
2025-04-21
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
Tanabe Pharma America, Inc.
Phase 1/2
27
California, Michigan, Ohio, Texas
2025-04-18
Active, closed
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
NCT06907511Pandemic Influenza Immunization, Healthy Volunteers
Sanofi
Phase 1/2
720
California, Florida, Georgia, Michigan, Nebraska, Ohio, South Carolina, Texas
2025-04-17
Recruiting
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
14
Colorado, Ohio
2025-04-17
Recruiting
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
NCT06909214New Onset Generalized Myasthenia Gravis (gMG)
DrugEfgartigimod PH20
argenx
Phase 4
30
California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Michigan, Ohio
2025-04-17
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06855160Chickenpox
DrugsMarketed varicella vaccine·Hepatitis A vaccine·MMR vaccine·PCV (pneumococcal conjugate vaccine) 13
GlaxoSmithKline
Phase 3
911
Arizona, California, Florida, Idaho, Ohio, Texas, Virginia
2025-04-17
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105Psoriatic Arthritis
DrugsLutikizumab·Risankizumab
AbbVie
Phase 2
120
California, Florida, Illinois, Maryland, Ohio, Pennsylvania, Tennessee, Texas
2025-04-11
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon
2025-04-11
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
California, Florida, Illinois, Kentucky, New Jersey, Ohio, Oregon, Texas
2025-04-08
Recruiting
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
NCT06708897CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
Lomond Therapeutics Holdings, Inc.
Phase 1
84
Kentucky, North Carolina, Ohio, Texas
2025-04-08
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
30
California, Florida, Missouri, Ohio, Texas
2025-04-07
Active, closed
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 3
43
California, District of Columbia, Florida, Kentucky, Michigan, North Carolina, Ohio, Texas
2025-04-07
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
DrugBitopertin
Disc Medicine, Inc
Phase 3
183
California, Florida, Massachusetts, Michigan, New York, North Carolina, Ohio, Texas
2025-04-04
Active, closed
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
NCT06776432Sleep Apnea
DrugAcetazolamide
Shionogi
Phase 2
60
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, South Carolina, Texas
2025-04-02
Active, closed
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
NCT06864169Gastrointestinal Cancer
DrugR-DXd
Merck Sharp & Dohme LLC
Phase 2
160
Connecticut, District of Columbia, Florida, Montana, New Jersey, Ohio, Virginia, Wisconsin
2025-04-01
Recruiting
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
NCT06340750Systemic Lupus Erythematosus
DrugBaff Car-T
Luminary Therapeutics
Phase 1
18
Ohio
2025-04-01
Recruiting
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain
NCT06908538Amputation, Amputation of Lower Limb, Amputation of Upper Limb, Amputation, Limb Loss
AtriCure, Inc.
Observational
2,000
Massachusetts, New Hampshire, New York, Ohio, South Carolina, Wisconsin
2025-04-01
Recruiting
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
NCT06592638Small Cell Lung Cancer
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
30
California, Florida, Kentucky, Ohio, Texas
2025-03-31
Recruiting
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450Advanced Solid Tumors Cancer, MSI-H Cancer
Nimbus Wadjet, Inc.
Phase 1/2
134
California, Illinois, Kentucky, New York, North Carolina, Ohio, Rhode Island, South Carolina
2025-03-31
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
DrugBalinatunfib
Sanofi
Phase 2
204
Arizona, Connecticut, Florida, Illinois, Michigan, New York, Ohio, Pennsylvania
2025-03-28
Active, closed
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
NCT06680427Aortic Stenosis Symptomatic
MiRus
Not applicable
30
California, Florida, Georgia, Minnesota, New Jersey, New York, Ohio
2025-03-26
Recruiting
ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
NCT06810518Inflammatory Bowel Disease (Crohn&#39;s Disease and Ulcerative Colitis), Inflammatory Bowel Syndrome
American Laboratory Products Company
Observational
220
Florida, New Hampshire, Ohio
2025-03-25
Active, closed
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648Stress Urinary Incontinence (SUI)
Acoustic Wave Cell Therapy, Inc.
Not applicable
130
Arizona, Florida, Idaho, Kansas, Montana, Nevada, Ohio, Texas
2025-03-25
Recruiting
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT06827613Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
DrugsSTAR0602·Sacituzumab Govitecan
Marengo Therapeutics, Inc.
Phase 1/2
50
California, Massachusetts, Ohio, Tennessee, Texas
2025-03-24
Recruiting
A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair
NCT06529835Peripheral Nerve Injuries
Auxilium Biotechnologies
Not applicable
80
California, Maryland, New York, Ohio, Pennsylvania, Texas
2025-03-21
Recruiting
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
NCT06874335Solid Tumor
DrugCemiplimab
Biohaven Therapeutics Ltd.
Phase 1
140
California, Colorado, Florida, Michigan, North Carolina, Ohio, South Carolina, Tennessee
2025-03-20
Recruiting
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
NCT06703489Ventricular Tachycardia (VT)
Medtronic Cardiac Ablation Solutions
Not applicable
60
Massachusetts, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-03-18
Recruiting
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
NCT06641362Bradycardia, Heart Failure, Ventricular Dysfunction
VDI Technologies
Observational
360
Arizona, Illinois, Minnesota, Ohio, Texas, Virginia
2025-03-18
Recruiting
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
NCT06805305Glioblastoma (GBM)
DrugsDOC1021·Temodar·Temozolomide
Diakonos Oncology Corporation
Phase 2
180
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2025-03-17
Recruiting
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
NCT06801002Solid Tumor
Jabez Bioscience, Inc
Phase 1
25
Ohio, Utah
2025-03-17
Active, closed
Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
NCT06495424Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
DrugCapsaicin
Averitas Pharma, Inc.
Observational
144
Delaware, Georgia, Kentucky, New Jersey, Ohio, Pennsylvania
2025-03-14
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
60
California, Illinois, Indiana, New York, Ohio, Texas
2025-03-13
Recruiting
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
NCT06788756Acute Myeloid Leukaemia (AML)
DrugCytarabine
Moleculin Biotech, Inc.
Phase 2/3
312
Alabama, Florida, Georgia, Nebraska, New Jersey, Ohio, Pennsylvania, Rhode Island
2025-03-12
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
DrugsRapamycin·Sirolimus
Umoja Biopharma
Phase 1
106
California, Illinois, Missouri, Nebraska, Ohio, Washington
2025-03-10
Recruiting
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06578624Solid Tumor
DrugPhase 2
Lamassu Bio Inc
Phase 1/2
70
Ohio
2025-03-10
Active, closed
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
DrugsCobolimab·Dostarlimab
GlaxoSmithKline
Phase 1/2
83
California, Iowa, New Jersey, Ohio, Rhode Island, Wisconsin
2025-03-06
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907Tumours, Gynecological
DrugsMo-Rez·Dostarlimab·Bevacizumab
GlaxoSmithKline
Phase 1/2
305
California, Colorado, New York, North Carolina, Ohio
2025-03-04
Recruiting
INHANCE Stemless Reverse Shoulder IDE
NCT06323980Arthroplasty, Replacement, Shoulder
DePuy Orthopaedics
Not applicable
168
Florida, Massachusetts, Michigan, Missouri, North Carolina, Ohio, Oregon, Pennsylvania
2025-03-04
Recruiting
CLAiR Pivotal Study
NCT06808334No Condition
Toku Eyes Ltd
Observational
942
Ohio
2025-02-27
Recruiting
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
NCT07558668Moderate to Severe Atopic Dermatitis
Sitryx Therapeutics Ltd
Phase 1
149
Arkansas, California, Indiana, Ohio, Pennsylvania, Utah
2025-02-26
Active, closed
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
NCT06738017Alpha 1-Antitrypsin Deficiency
BioMarin Pharmaceutical
Phase 1
6
California, Missouri, Ohio, South Carolina
2025-02-21
Recruiting
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
NCT06826612Huntington Disease
Hoffmann-La Roche
Phase 1/2
53
Massachusetts, Ohio, Pennsylvania
2025-02-21
Recruiting
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
20
Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas
2025-02-21
Rows per page Showing 1–500 of 1263
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/ohio

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,263 of those studies with a site in Ohio.

How many clinical trials are recruiting in Ohio?

737 of the 1,263 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 32 have not yet opened recruitment, 450 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ohio), 1,263 studies
PhaseStudiesRecruitingShare
Phase 324211719.2%
Phase 221811517.3%
Phase 120912516.5%
Not applicable20512216.2%
Phase 1/218912815%
Observational1519312%
Phase 2/326182.1%
Phase 422191.7%
Phase EARLY_PHASE1100.1%

Most active sponsors

Lead sponsors with the most studies (Ohio)
Lead sponsorStudiesRecruiting
AstraZeneca3614
Novartis Pharmaceuticals2816
Hoffmann-La Roche258
Merck Sharp & Dohme LLC2012
GlaxoSmithKline1913
Pfizer178
AbbVie1610
Takeda1612
Bristol-Myers Squibb1510
Janssen Research & Development, LLC158
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.